In our study, we selected NB4 cells, which express the HLA-A*1101 allele of MHC class I, the most common allele of MHC class I in China, to screen DAC treatment specific CTA, therefore the resulted CTAs should be more compatible to AML patients with HLA-A*1101 allele. The gene discussed is HLA-A; the disease is acute myeloid leukemia.